| answer text |
<p>NHS England has made an assessment of the need for national treatment decisions
as to the commissioning of systemic therapies for neuroendocrine carcinomas. Based
on this assessment, it has discussed the issue with the National Institute for Health
and Care Excellence (NICE) and NICE has agreed to do a multiple technology appraisal
of lanreotide, sunitinib, everolimus and peptide receptor radionuclide therapy. NICE
guidance on these treatments is due in the summer of 2017. In the meantime, sunitinib
is available from the Cancer Drugs Fund and lanreotide is available through routine
commissioning.</p>
|
 |
